217 related articles for article (PubMed ID: 18719047)
1. Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study.
Bellino S; Paradiso E; Bozzatello P; Bogetto F
J Psychopharmacol; 2010 Mar; 24(3):333-9. PubMed ID: 18719047
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of quetiapine in the treatment of borderline personality disorder: A pilot study.
Bellino S; Paradiso E; Bogetto F
J Clin Psychiatry; 2006 Jul; 67(7):1042-6. PubMed ID: 16889446
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of aripiprazole augmentation in sertraline-resistant patients with borderline personality disorder.
Bellino S; Paradiso E; Bogetto F
Psychiatry Res; 2008 Nov; 161(2):206-12. PubMed ID: 18848360
[TBL] [Abstract][Full Text] [Related]
4. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study.
Bellino S; Paradiso E; Bogetto F
J Clin Psychiatry; 2005 Sep; 66(9):1111-5. PubMed ID: 16187767
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
Bozzatello P; Rocca P; Uscinska M; Bellino S
CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine is effective in treating depression in multiple sclerosis patients: an open-label multicenter study.
Solaro C; Bergamaschi R; Rezzani C; Mueller M; Trabucco E; Bargiggia V; Dematteis F; Mattioda A; Cimino V; Restivo D; Patti F; Cavalla P
Clin Neuropharmacol; 2013; 36(4):114-6. PubMed ID: 23783007
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine for premenstrual dysphoric disorder: a pilot study.
Mazza M; Harnic D; Catalano V; Janiri L; Bria P
Expert Opin Pharmacother; 2008 Mar; 9(4):517-21. PubMed ID: 18312154
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
11. Manic switching in patients receiving duloxetine.
de Dios C; Ezquiaga E
Am J Psychiatry; 2007 Jul; 164(7):1121. PubMed ID: 17606669
[No Abstract] [Full Text] [Related]
12. A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode.
Martinez JM; Katon W; Greist JH; Kroenke K; Thase ME; Meyers AL; Edwards SE; Marangell LB; Shoemaker S; Swindle R
Int Clin Psychopharmacol; 2012 Jan; 27(1):17-26. PubMed ID: 22027844
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine in major depressed patients resistant to SSRIs and/or venlafaxine.
Pitchot W; Scantamburlo G; Ansseau M
Psychiatr Danub; 2010 Nov; 22 Suppl 1():S106-7. PubMed ID: 21057413
[TBL] [Abstract][Full Text] [Related]
14. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
15. Open-label support for duloxetine for the treatment of panic disorder.
Simon NM; Kaufman RE; Hoge EA; Worthington JJ; Herlands NN; Owens ME; Pollack MH
CNS Neurosci Ther; 2009; 15(1):19-23. PubMed ID: 19228176
[TBL] [Abstract][Full Text] [Related]
16. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
Berk M; du Plessis AD; Birkett M; Richardt D
Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
[TBL] [Abstract][Full Text] [Related]
17. Rescue pharmacotherapy with duloxetine for selective serotonin reuptake inhibitor nonresponders in late-life depression: outcome and tolerability.
Karp JF; Whyte EM; Lenze EJ; Dew MA; Begley A; Miller MD; Reynolds CF
J Clin Psychiatry; 2008 Mar; 69(3):457-63. PubMed ID: 18251622
[TBL] [Abstract][Full Text] [Related]
18. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
[TBL] [Abstract][Full Text] [Related]
20. Duloxetine in the treatment of major depressive disorder: an open-label study.
Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
